Nephro Care India LimitedNEPHROCARECorporate

Healthcare Latest results: Jun 2026 4 quarters of data
₹85.40
MCap ₹141 Cr
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹29 Cr
Sales · Jun 2026
+68.4% YoY
₹4 Cr
Operating Profit · Jun 2026
+502.8% YoY
12.4%
OPM % · Jun 2026
+254.3% YoY
₹2 Cr
Net Profit · Jun 2026
+347.4% YoY
₹0.98
EPS · Jun 2026
+351.3% YoY

📝 Nephro Care India Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Nephro Care India Limited reported revenue of ₹29 crore for the quarter ended June 2026 (Q1 FY27), up 68.4% from ₹17 crore in the same quarter last year, and up 9.1% sequentially over the March 2026 quarter.

The company swung to a net profit of ₹2 crore from a net loss of ₹1 crore a year earlier. Earnings per share (EPS) came in at ₹0.98.

Operating profit stood at ₹4 crore — an operating margin (OPM) of 12.4%, compared with 3.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Nephro Care India Limited posted revenue of ₹67 crore, with a net profit of ₹1 crore.

Valuation snapshot

At the current price of ₹85.40, NEPHROCARE has a market capitalisation of ₹141 crore.

Within the Healthcare industry, it is the 14th-largest of the 22 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 61.71%, foreign institutional investors (FIIs) 0.73%, domestic institutional investors (DIIs) 1.30%, public shareholders 36.27% of Nephro Care India Limited.

Promoter holding rose from 61.47% to 61.71% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹141 Cr
Current Price ?
₹85.4
P/E ?
N/A
Industry P/E ?
34.70
P/B ?
2.48
P/S ?
N/A
P/FCF ?
-25.19
Enterprise Value ?
₹141 Cr
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
N/A
OPM ?
N/A
Profit after tax (TTM) ?
N/A
EPS (TTM) ?
N/A
ROCE ?
8.7%
ROE ?
N/A
ROA ?
N/A
Growth
Sales — latest qtr ?
₹29 Cr
PAT — latest qtr ?
₹2 Cr
YoY qtr sales growth ?
68.4%
YoY qtr profit growth ?
347.4%
Sales growth (3y) ?
73%
Sales growth (5y) ?
118%
Profit growth (3y) ?
12%
Profit growth (5y) ?
106%
Financial Health
Debt ?
₹0 Cr
Debt to Equity ?
0.00
Interest Coverage ?
2.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
61.71%
Change in promoter holding ?
0.33%
Pledged percentage ?
N/A
Market
Return 3 months ?
30.5%
Return 6 months ?
-0.8%

🗓️ Quarterly results (4 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Jun 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 17232729 +68.4% +9.1%
Operating Profit 1224 +502.8% +79.0%
Other Income 0010 +346.4% -73.1%
Interest 00-00 -75.3% +446.0%
Depreciation 1121 +2.9% -23.5%
Profit Before Tax -1113 +501.8% +100.9%
Net Profit -1012 +347.4% +60.8%
EPS -0.390.250.610.98 +351.3% +60.7%
OPM % 3.5% 8.4% 7.6% 12.4% +254.3% +63.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric Prev FY FY26 TTM YoY %
Sales — ₹67 Cr — —
Operating Profit — ₹5 Cr — —
OPM % — 6.79% — —
NPM % — 1.15% — —
Other Income — ₹1 Cr — —
Depreciation — ₹4 Cr — —
Interest — ₹0 Cr — —
EBIT — ₹0 Cr — —
PBT — ₹1 Cr — —
Tax — — — —
Net Profit — ₹1 Cr — —
EPS — ₹0.47 — —
Material Cost — — — —
Employee Cost — — — —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 0.5011.9016.4916.49 +0.0%
Reserves 2.033.1237.0040.37 +9.1%
Borrowings 2.480.000.000.00 —
Other Liabilities 3.255.9414.7915.81 +6.9%
Total Liabilities 8.2620.9668.2872.67 +6.4%
Fixed Assets 3.014.7431.4834.12 +8.4%
CWIP 0.000.860.610.43 -29.5%
Investments 2.006.5118.5811.82 -36.4%
Other Assets 3.258.8517.6126.30 +49.3%
Total Assets 8.2620.9668.2872.67 +6.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 4.120.917.822.21 -71.7%
Cash from Investing Activity -2.33-7.54-39.56-0.48 +98.8%
Cash from Financing Activity -0.085.6035.100.00 -100.0%
Net Cash Flow 1.71-1.033.371.73 -48.7%
Free Cash Flow 3.62-2.38-21.98-5.59 +74.6%
CFO/OP 121%50%154%48% -68.8%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 0.852.0125.6124.85 -3.0%
Inventory Days 35.2514.0734.3831.68 -7.9%
Days Payable 69.0375.17107.3292.84 -13.5%
Cash Conversion Cycle -32.93-59.09-47.33-36.31 +23.3%
Working Capital Days -56.81-36.86-51.2337.10 +172.4%
ROCE % 65.84%60.41%11.27%8.70% -22.8%

👥 Shareholding (latest 4 periods)

Metric Dec 2024Mar 2025Sep 2025Mar 2026 % Chg
Promoters 61.38%61.44%61.47%61.71% +0.4%
FIIs 4.06%3.50%3.47%0.73% -79.0%
DIIs 3.41%2.24%1.04%1.30% +25.0%
Public 31.14%32.82%34.02%36.27% +6.6%
No. of Shareholders 1,0771,3911,6441,845 +12.2%

⚖️ Peer comparison

Industry: Healthcare · 22 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 VIJAYA Vijaya Diagnostic ₹1,507.80 15,530 82.7 857 187 42.3% 21.8% 19.5% 20.2% 22.8% 37.3%
2 METROPOLIS Metropolis Healthcare ₹596.30 12,370 61.1 1,710 203 24.7% 11.9% 23.6% 31.4% 16.6% 25.7%
3 HCG Healthcare Global ₹704.05 10,512 390.9 2,626 33 18.2% 1.3% 14.6% -53.3% 13.1% 175.3%
4 YATHARTH Yatharth Hospital ₹988.90 9,528 54.1 1,200 171 23.6% 14.3% 36.2% 31.6% 47.6% 16.2%
5 JLHL Jupiter Life ₹277.85 9,109 9.7 1,557 187 22.1% 12.0% 20.9% -6.7% 18.2% -14.5%
6 THYROCARE Thyrocare Technologies ₹555.45 8,841 50.0 876 176 32.1% 20.1% 20.8% 79.4% 24.3% 33.2%
7 KOVAI Kovai Medical ₹6,260.50 6,850 26.7 1,644 256 27.9% 15.6% 15.7% 16.7% 15.3% 20.6%
8 INDRAMEDCO Indraprastha Medical ₹363.20 3,330 17.7 1,524 188 18.0% 12.4% 9.3% 13.7% 11.3% 9.5%
9 KRSNAA Krsnaa Diagnostics ₹543.40 1,763 18.1 816 98 26.8% 12.0% 7.8% 31.0% 22.1% -19.3%
10 SURAKSHA Suraksha Diagnostic ₹311.85 1,624 45.3 325 35 31.4% 10.8% 23.1% 1.4% 20.7% 40.0%
11 SHALBY Shalby ₹132.15 1,418 38.0 1,176 37 12.1% 3.2% 5.0% 1683.0% 11.7% 36.7%
12 GPTHEALTH GPT Healthcare ₹157.90 1,296 27.4 491 48 18.5% 9.8% 15.1% -21.9% 17.8% 62.5%
13 LAXMIDENTL Laxmi Dental ₹196.21 1,080 35.0 287 31 16.2% 10.9% 16.0% -10.1% 13.2% 28.9%
14 NEPHROCARE Nephro Care ₹234.80 387 — — — — — — — 68.4% 347.7%
15 LOTUSEYE Lotus Eye ₹114.50 243 n/m 57 0 8.5% 0.3% 8.4% -89.1% 26.2% 13.0%
16 UNIHEALTH Unihealth Hospitals ₹121.00 190 6.5 132 46 40.9% 34.8% — — 104.6% 71.5%
17 MADHAVBAUG Vaidya Sane ₹148.00 156 19.1 147 8 11.4% 5.6% — — 116.1% 94.3%
18 MHHL Mohini Health ₹57.05 104 — 145 -17 -1.4% -11.7% — — -6.6% -1400.0%
19 MAITREYA Maitreya Medicare ₹120.65 82 — 45 -2 -1.0% -5.5% — — -5.2% -1720.0%
20 AATMAJ Aatmaj Healthcare ₹26.75 60 83.6 24 1 9.7% 2.9% — — 22.5% -39.4%
21 NIDAN Nidan Laborator. ₹33.00 46 30.6 26 2 19.0% 5.9% — — -11.2% -92.0%
22 ARTEMISMED Artemis Medicare ₹315.00 — 48.0 1,081 103 17.4% 9.6% 15.4% 25.9% 16.3% 30.9%
❓ Frequently asked questions
What was Nephro Care India Limited's revenue in Q1 FY27?
Nephro Care India Limited reported revenue of ₹29 crore for the quarter ended June 2026 (Q1 FY27), up 68.4% from ₹17 crore in the same quarter last year, and up 9.1% sequentially over the March 2026 quarter.
What was Nephro Care India Limited's net profit in Q1 FY27?
The company swung to a net profit of ₹2 crore from a net loss of ₹1 crore a year earlier. Earnings per share (EPS) came in at ₹0.98.
What is NEPHROCARE's market capitalisation and P/E ratio?
At the current price of ₹85.40, NEPHROCARE has a market capitalisation of ₹141 crore.
Who owns Nephro Care India Limited? (shareholding pattern)
As of Mar 2026, promoters held 61.71%, foreign institutional investors (FIIs) 0.73%, domestic institutional investors (DIIs) 1.30%, public shareholders 36.27% of Nephro Care India Limited.
TTM ends N/A. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI